Rare NGR1 Fusion - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510250274

Publication Date:

October 5, 2024

Pages:

101

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

NGR1 fusion, also known as NTRK1 fusion, is a genetic alteration in which the NTRK1 gene fuses with another gene, resulting in an abnormal fusion protein. The NTRK1 gene is part of the neurotrophic tyrosine receptor kinase (NTRK) family, which plays a crucial role in the development and functioning of nerve cells. NTRK1 fusions can lead to uncontrolled cell growth and are associated with certain rare cancer types.
The global market for Rare NGR1 Fusion was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rare NGR1 Fusion, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Rare NGR1 Fusion by region & country, by Type, and by Application.
The Rare NGR1 Fusion market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rare NGR1 Fusion.
Market Segmentation
By Company
Elevation Oncology
Merus
Hummingbird Bioscience
Boehringer Ingelheim
CANbridge Pharmaceuticals
Salubris Biotherapeutics
AVEO Oncology
Rain Therapeutics
Eli Lilly and Company
Jiangsu Hengrui Medicine
Segment by Type:
Immunotherapy
Chemotherapy
Radiation Therapy
Segment by Application
Hospital
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Rare NGR1 Fusion manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Rare NGR1 Fusion in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Rare NGR1 Fusion in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Rare NGR1 Fusion Product Introduction
1.2 Global Rare NGR1 Fusion Market Size Forecast
1.3 Rare NGR1 Fusion Market Trends & Drivers
1.3.1 Rare NGR1 Fusion Industry Trends
1.3.2 Rare NGR1 Fusion Market Drivers & Opportunity
1.3.3 Rare NGR1 Fusion Market Challenges
1.3.4 Rare NGR1 Fusion Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Rare NGR1 Fusion Players Revenue Ranking (2023)
2.2 Global Rare NGR1 Fusion Revenue by Company (2019-2024)
2.3 Key Companies Rare NGR1 Fusion Manufacturing Base Distribution and Headquarters
2.4 Key Companies Rare NGR1 Fusion Product Offered
2.5 Key Companies Time to Begin Mass Production of Rare NGR1 Fusion
2.6 Rare NGR1 Fusion Market Competitive Analysis
2.6.1 Rare NGR1 Fusion Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Rare NGR1 Fusion Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rare NGR1 Fusion as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Immunotherapy
3.1.2 Chemotherapy
3.1.3 Radiation Therapy
3.2 Global Rare NGR1 Fusion Sales Value by Type
3.2.1 Global Rare NGR1 Fusion Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Rare NGR1 Fusion Sales Value, by Type (2019-2030)
3.2.3 Global Rare NGR1 Fusion Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinics
4.1.3 Others
4.2 Global Rare NGR1 Fusion Sales Value by Application
4.2.1 Global Rare NGR1 Fusion Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Rare NGR1 Fusion Sales Value, by Application (2019-2030)
4.2.3 Global Rare NGR1 Fusion Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Rare NGR1 Fusion Sales Value by Region
5.1.1 Global Rare NGR1 Fusion Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Rare NGR1 Fusion Sales Value by Region (2019-2024)
5.1.3 Global Rare NGR1 Fusion Sales Value by Region (2025-2030)
5.1.4 Global Rare NGR1 Fusion Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Rare NGR1 Fusion Sales Value, 2019-2030
5.2.2 North America Rare NGR1 Fusion Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Rare NGR1 Fusion Sales Value, 2019-2030
5.3.2 Europe Rare NGR1 Fusion Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Rare NGR1 Fusion Sales Value, 2019-2030
5.4.2 Asia Pacific Rare NGR1 Fusion Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Rare NGR1 Fusion Sales Value, 2019-2030
5.5.2 South America Rare NGR1 Fusion Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Rare NGR1 Fusion Sales Value, 2019-2030
5.6.2 Middle East & Africa Rare NGR1 Fusion Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Rare NGR1 Fusion Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Rare NGR1 Fusion Sales Value
6.3 United States
6.3.1 United States Rare NGR1 Fusion Sales Value, 2019-2030
6.3.2 United States Rare NGR1 Fusion Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Rare NGR1 Fusion Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Rare NGR1 Fusion Sales Value, 2019-2030
6.4.2 Europe Rare NGR1 Fusion Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Rare NGR1 Fusion Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Rare NGR1 Fusion Sales Value, 2019-2030
6.5.2 China Rare NGR1 Fusion Sales Value by Type (%), 2023 VS 2030
6.5.3 China Rare NGR1 Fusion Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Rare NGR1 Fusion Sales Value, 2019-2030
6.6.2 Japan Rare NGR1 Fusion Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Rare NGR1 Fusion Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Rare NGR1 Fusion Sales Value, 2019-2030
6.7.2 South Korea Rare NGR1 Fusion Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Rare NGR1 Fusion Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Rare NGR1 Fusion Sales Value, 2019-2030
6.8.2 Southeast Asia Rare NGR1 Fusion Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Rare NGR1 Fusion Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Rare NGR1 Fusion Sales Value, 2019-2030
6.9.2 India Rare NGR1 Fusion Sales Value by Type (%), 2023 VS 2030
6.9.3 India Rare NGR1 Fusion Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Elevation Oncology
7.1.1 Elevation Oncology Profile
7.1.2 Elevation Oncology Main Business
7.1.3 Elevation Oncology Rare NGR1 Fusion Products, Services and Solutions
7.1.4 Elevation Oncology Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.1.5 Elevation Oncology Recent Developments
7.2 Merus
7.2.1 Merus Profile
7.2.2 Merus Main Business
7.2.3 Merus Rare NGR1 Fusion Products, Services and Solutions
7.2.4 Merus Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.2.5 Merus Recent Developments
7.3 Hummingbird Bioscience
7.3.1 Hummingbird Bioscience Profile
7.3.2 Hummingbird Bioscience Main Business
7.3.3 Hummingbird Bioscience Rare NGR1 Fusion Products, Services and Solutions
7.3.4 Hummingbird Bioscience Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.3.5 Boehringer Ingelheim Recent Developments
7.4 Boehringer Ingelheim
7.4.1 Boehringer Ingelheim Profile
7.4.2 Boehringer Ingelheim Main Business
7.4.3 Boehringer Ingelheim Rare NGR1 Fusion Products, Services and Solutions
7.4.4 Boehringer Ingelheim Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.4.5 Boehringer Ingelheim Recent Developments
7.5 CANbridge Pharmaceuticals
7.5.1 CANbridge Pharmaceuticals Profile
7.5.2 CANbridge Pharmaceuticals Main Business
7.5.3 CANbridge Pharmaceuticals Rare NGR1 Fusion Products, Services and Solutions
7.5.4 CANbridge Pharmaceuticals Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.5.5 CANbridge Pharmaceuticals Recent Developments
7.6 Salubris Biotherapeutics
7.6.1 Salubris Biotherapeutics Profile
7.6.2 Salubris Biotherapeutics Main Business
7.6.3 Salubris Biotherapeutics Rare NGR1 Fusion Products, Services and Solutions
7.6.4 Salubris Biotherapeutics Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.6.5 Salubris Biotherapeutics Recent Developments
7.7 AVEO Oncology
7.7.1 AVEO Oncology Profile
7.7.2 AVEO Oncology Main Business
7.7.3 AVEO Oncology Rare NGR1 Fusion Products, Services and Solutions
7.7.4 AVEO Oncology Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.7.5 AVEO Oncology Recent Developments
7.8 Rain Therapeutics
7.8.1 Rain Therapeutics Profile
7.8.2 Rain Therapeutics Main Business
7.8.3 Rain Therapeutics Rare NGR1 Fusion Products, Services and Solutions
7.8.4 Rain Therapeutics Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.8.5 Rain Therapeutics Recent Developments
7.9 Eli Lilly and Company
7.9.1 Eli Lilly and Company Profile
7.9.2 Eli Lilly and Company Main Business
7.9.3 Eli Lilly and Company Rare NGR1 Fusion Products, Services and Solutions
7.9.4 Eli Lilly and Company Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.9.5 Eli Lilly and Company Recent Developments
7.10 Jiangsu Hengrui Medicine
7.10.1 Jiangsu Hengrui Medicine Profile
7.10.2 Jiangsu Hengrui Medicine Main Business
7.10.3 Jiangsu Hengrui Medicine Rare NGR1 Fusion Products, Services and Solutions
7.10.4 Jiangsu Hengrui Medicine Rare NGR1 Fusion Revenue (US$ Million) & (2019-2024)
7.10.5 Jiangsu Hengrui Medicine Recent Developments
8 Industry Chain Analysis
8.1 Rare NGR1 Fusion Industrial Chain
8.2 Rare NGR1 Fusion Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Rare NGR1 Fusion Sales Model
8.5.2 Sales Channel
8.5.3 Rare NGR1 Fusion Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Elevation Oncology
Merus
Hummingbird Bioscience
Boehringer Ingelheim
CANbridge Pharmaceuticals
Salubris Biotherapeutics
AVEO Oncology
Rain Therapeutics
Eli Lilly and Company
Jiangsu Hengrui Medicine

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂